Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.
Clinical data | |
---|---|
Routes of administration | intravenous (?) |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C36H39NO5 |
Molar mass | 565.710 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Mechanism of action
editCinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1]
See also
edit- Riociguat, another drug stimulating sGC, but with a different mechanism
- PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.
References
edit- ^ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009